Brief: Inhibikase Therapeutics Reports 2022 Loss Per Share Of $0.72
31/03/2023 13:25
March 31 (Reuters) - Inhibikase Therapeutics Inc
IKT.O :
* INHIBIKASE THERAPEUTICS REPORTS FULL YEAR 2022 FINANCIAL
RESULTS
AND HIGHLIGHTS RECENT PERIOD ACTIVITY
* INHIBIKASE THERAPEUTICS INC - FY LOSS PER SHARE $0.72
* INHIBIKASE THERAPEUTICS INC - EXPECTS THAT EXISTING CASH
AND
CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS INTO Q4
OF 2024
Source text for Eikon: ID:nPn3YL97Za
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary